

浏览全部资源
扫码关注微信
1.浙江中医药大学,浙江省杭州市滨江区滨文路548号,310053
2.杭州市上城区清波街道社区卫生服务中心
3.杭州市滨江区浦沿街道社区卫生服务中心
Received:06 August 2025,
Revised:2025-09-30,
Published:17 December 2025
移动端阅览
王蓉芸,华丽江山,李小燕等.参芪膏治疗脾肾亏虚型老年肌少症的随机双盲对照试验[J].中医杂志,2025,66(24):2553-2563.
WANG Rongyun,HUA Lijiangshan,LI Xiaoyan,et al.Shengqi Paste (参芪膏) for Senile Sarcopenia with Spleen-Kidney Deficiency Syndrome:A Randomized Double-Blind Controlled Trial[J].Journal of Traditional Chinese Medicine,2025,66(24):2553-2563.
王蓉芸,华丽江山,李小燕等.参芪膏治疗脾肾亏虚型老年肌少症的随机双盲对照试验[J].中医杂志,2025,66(24):2553-2563. DOI: 10.13288/j.11-2166/r.2025.24.009.
WANG Rongyun,HUA Lijiangshan,LI Xiaoyan,et al.Shengqi Paste (参芪膏) for Senile Sarcopenia with Spleen-Kidney Deficiency Syndrome:A Randomized Double-Blind Controlled Trial[J].Journal of Traditional Chinese Medicine,2025,66(24):2553-2563. DOI: 10.13288/j.11-2166/r.2025.24.009.
目的
2
观察参芪膏治疗脾肾亏虚型老年肌少症的临床疗效和安全性。
方法
2
选取社区老年肌少症患者150例,随机分为治疗组和对照组各75例,治疗组口服参芪膏,对照组口服参芪膏模拟剂,两组疗程均为12周。比较两组患者治疗前后肌少症的改善情况[包括骨骼肌质量指数(SMI)、握力和五次起坐时间],比较两组治疗前后中医证候评分及健康状况[包括身体质量指数(BMI)、衰弱量表(FRAIL)、营养状况简表(MNA-SF)、国际体力活动量表(IPAQ)、日常生活能力评分量表(ADL)、匹兹堡睡眠质量指数评价量表(PSQI)和简易老年抑郁量表(GDS-15)]。比较两组治疗前后血清肌肉生长抑制素(MSTN),鸢尾素(irisin)、肿瘤坏死因子α(TNF-α)、白细胞介素1β(IL-1β)、白细胞介素6(IL-6)和白细胞介素10(IL-10)水平,并通过液相色谱-质谱法(LC-MS)分析治疗后两组患者血清代谢物的变化。
结果
2
与本组治疗前比较,治疗后治疗组SMI和握力值均提升(
P
<0.01),两组患者的五次起坐时间均缩短(
P
<0.01),除对照组夜尿频多症状差异无统计学意义(
P
>0.05)外,两组其余各症状评分及中医证候评分均明显降低(
P
<0.01),治疗组BMI与MNA-SF、IPAQ评分及血清IL-10水平均升高,FRAIL、ADL、PSQI、GDS-15评分和血清MSTN、irisin、TNF-α、IL-1β水平均降低,对照组ADL评分与血清MSTN、irisin水平均降低,IPAQ评分升高(
P
<0.05或
P
<0.01);两组患者治疗后比较,治疗组SMI、握力均高于对照组,而五次起坐时间均低于对照组(
P
<0.05或
P
<0.01),治疗组倦怠乏力、畏寒肢冷、腰膝酸软、失眠症状评分和中医证候评分均低于对照组(
P
<0.01),BMI及MNA-SF、IPAQ评分均高于对照组,ADL、PSQI、GDS-15评分均低于对照组(
P
<0.05或
P
<0.01)。治疗后治疗组血清MSTN、irisin、TNF-α、IL-1β水平均降低,IL-10水平升高(
P
<0.05或
P
<0.01);对照组血清MSTN和irisin均降低(
P
<0.01)。血清代谢组学结果提示,治疗后治疗组和对照组之间血清代谢产物存在差异,治疗后两组间筛选出排名前10的差异代谢物涉及17个相关通路。
结论
2
参芪膏可以有效改善老年肌少症患者的肌肉质量和肌肉力量,降低患者的炎症状态,调节代谢紊乱,增加营养水平,提高生活质量,且安全性较好。
Objective
2
To evaluate the clinical effectiveness and safety of
Shengqi Paste
(参芪膏) for senile sarcopenia with spleen-kidney deficiency syndrome.
Methods
2
A total of 150 elderly patients with sarcopenia from the community were selected and randomly divided into a treatment group and a control group, with 75 participants in each group. The treatment group was given
Shenqi Paste
orally, while the control group was given a
Shenqi Paste
placebo orally. Both groups received treatment for a course of 12 weeks. The improvement of sarcopenia after treatment in the two groups was
compared, including skeletal muscle mass index (SMI), grip strength, and time for five chair stands. The scores of traditional Chinese medicine (TCM) syndromes and health status indicators were also compared before and after treatment, including body mass index (BMI), FRAIL scale (Fatigue, Resistance, Ambulation, Illness, Loss of weight scale), Mini Nutritional Assessment-Short Form (MNA-SF), International Physical Activity Questionnaire (IPAQ), Activities of Daily Living (ADL) scale, Pittsburgh Sleep Quality Index (PSQI), and Geriatric Depression Scale-Short Form (GDS-15). Additionally, the serum levels of myostatin (MSTN), irisin, tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β), interleukin-6 (IL-6), and interleukin-10 (IL-10) were compared between groups before and after treatment. Changes in serum metabolites of patients in both groups after treatment were analyzed by liquid chromatography-mass spectrometry (LC-MS).
Results
2
Compared with the baseline (before treatment) within group, the SMI and grip strength in the treatment group significantly increased after treatment (
P
<0.01); the time for five chair stands shortened in both groups (
P
<0.01). Except for no significant difference in the symptom of more frequent nocturia in the control group (
P
>0.05), the scores of other individual TCM symptoms and the total TCM syndrome score significantly decreased in both groups (
P
<0.01). In the treatment group, BMI, MNA-SF score, IPAQ score, and serum IL-10 level all increased, while FRAIL scale score, ADL score, PSQI score, GDS-15 score, and serum levels of MSTN, irisin, TNF-α, and IL-1β decreased; in the control group, ADL score serum levels of MSTN and irisin decreased, IPAQ score increased (
P
<0.05 or
P
<0.01). Compared between groups after treatment, the SMI and grip strength in the treatment group were higher than those in the control group, while the time for five chair stands
was shorter than that in the control group (
P
<0.05 or
P
<0.01); the scores of fatigue and weakness, fear of cold and cold limbs, soreness and weakness of waist and knees, insomnia, and the total TCM syndrome score in the treatment group were lower than those in the control group (
P
<0.01). BMI, MNA-SF score, IPAQ score in the treatment group were higher than those in the control group, while the ADL score, PSQI score and GDS score-15 were lower than those in the control group (
P
<0.05 or
P
<0.01). Compared with the baseline within group, serum levels of MSTN, irisin, TNF-α, and IL-1β decreased in the treatment group after treatment, while IL-10 increased (
P
<0.05 or
P
<0.01); serum MSTN and irisin levels decreased in the control group (
P
<0.01). Serum meta-bolomics results indicated differences in serum metabolites between the treatment and control groups after treatment, and the top 10 differential metabolites screened between groups after treatment were involved in 17 related metabolic pathways.
Conclusion
2
Shenqi Paste
can effectively improve muscle mass and muscle strength in elderly patients with sarcopenia, reduce the inflammatory state of patients, regulate metabolic disorders, increase nutritional levels, improve quality of life, and show good safety.
SAYER AA , COOPER R , ARAI H , et al . Sarcopenia [J]. Nat Rev Dis Primers , 2024 , 10 ( 1 ): 68 .
SHU X , LIN T , WANG H , et al . Diagnosis, prevalence, and mortality of sarcopenia in dialysis patients: a systematic review and meta-analysis [J]. J Cachexia Sarcopenia Muscle , 2022 , 13 ( 1 ): 145 - 158 .
DUARTE MP , ALMEIDA LS , NERI SGR , et al . Prevalence of sarcopenia in patients with chronic kidney disease: a global systematic review and meta-analysis [J]. J Cachexia Sarcopenia Muscle , 2024 , 15 ( 2 ): 501 - 512 .
ANKER SD , MORLEY JE , VON HAEHLING S . Welcome to the ICD-10 code for sarcopenia [J]. J Cachexia Sarcopenia Muscle , 2016 , 7 ( 5 ): 512 - 514 .
PETERMANN-ROCHA F , BALNTZI V , GRAY SR , et al . Global prevalence of sarcopenia and severe sarcopenia: a systematic review and meta-analysis [J]. J Cachexia Sarcopenia Muscle , 2022 , 13 ( 1 ): 86 - 99 .
WANG Y , ZHANG Y , LANE N E , et al . Population-based metagenomics analysis reveals altered gut micro-biome in sarcopenia: data from the Xiangya sarcopenia study [J]. J Cachexia Sarcopenia Muscle , 2022 , 13 ( 5 ): 2340 - 2351 .
BRUYERE O , BEAUDART C , ETHGEN O , et al . The health economics burden of sarcopenia: a systematic review [J]. Maturitas , 2019 , 119 : 61 - 69 . doi: 10.1016/j.maturitas.2018.11.003 http://dx.doi.org/10.1016/j.maturitas.2018.11.003 .
崔华 , 王朝晖 , 吴剑卿 , 等 . 老年人肌少症防控干预中国专家共识(2023) [J]. 中华老年医学杂志 , 2024 , 42 ( 2 ): 144 - 153 .
何盼 , 陈磊 , 连让平 , 等 . 中医药防治肌少症的研究进展 [J]. 中草药 , 2025 , 56 ( 10 ): 3729 - 3738 .
魏巍 , 戚晓楠 , 谢鹏 , 等 . 中医药治疗肌少症的方法及其作用机制研究最新进展 [J]. 世界中医药 , 2024 , 19 ( 20 ): 3191 - 3198 .
CHEN L , WOO J , ASSANTACHAI P , et al . Asian Working Group for Sarcopenia: 2019 consensus update on sarcopenia diagnosis and treatment [J]. J Am Med Dir Assoc , 2020 , 21 ( 3 ): 300 - 307 .
国家市场监督管理总局 . 中医临床诊疗术语 第2部分:证候 [S]. 北京 : 中国标准出版社 , 2021 : 225 .
宋云 . 补肾活血健脾方对肌少-骨质疏松症的临床疗效观察 [D]. 济南 : 山东中医药大学 , 2023 .
郑筱萸 . 中药新药临床研究指导原则(试行) [M]. 北京 : 中国医药科技出版社 , 2002 : 361 - 390 .
NG YX , CHENG LJ , QUEK YY , et al . The measurement properties and feasibility of FRAIL scale in older adults: a systematic review and meta-analysis [J]. Ageing Res Rev , 2024 , 95 : 102243 . doi: 10.1016/j.arr.2024. 102243 http://dx.doi.org/10.1016/j.arr.2024.102243 .
刘家硕 , 朴哲 , 杨瑞丽 , 等 . 三种营养风险筛查工具对老年脑卒中住院患者的筛查与比较 [J]. 中国老年学杂志 , 2020 , 40 ( 20 ): 4286 - 4288 .
屈宁宁 , 李可基 . 国际体力活动问卷中文版的信度和效度研究 [J]. 中华流行病学杂志 , 2004 , 25 ( 3 ): 87 - 90 .
CRAI CL , MARSHALL AL , SJOSTROM M , et al . International physical activity questionnaire: 12-country reliability and validity [J]. Med Sci Sports Exerc , 2003 , 35 ( 8 ): 1381 - 1395 .
翁映虹 , 黄坚红 . 阿尔茨海默病评定量表-认知部分中文版与日常生活能力量表评价血管性痴呆的信度与效度 [J]. 中国老年学杂志 , 2014 , 34 ( 7 ): 1751 - 1753 .
刘贤臣 , 唐茂芹 , 胡蕾 , 等 . 匹兹堡睡眠质量指数的信度和效度研究 [J]. 中华精神科杂志 , 1996 , 29 ( 2 ): 103 - 107 .
唐丹 . 简版老年抑郁量表(GDS-15)在中国老年人中的使用 [J]. 中国临床心理学杂志 , 2013 ( 3 ): 402 - 405 .
刘晏东 , 邓强 , 彭冉东 , 等 . 基于“肝-脾-肾”轴探讨中医药防治肌少-骨质疏松 [J]. 中国老年学杂志 , 2024 , 44 ( 23 ): 5878 - 5883 .
詹云帆 , 柴永利 , 严华美 , 等 . 上海社区老年人肌少症中医证候调查研究 [J]. 上海中医药杂志 , 2025 , 59 ( 2 ): 49 - 54 .
谢凌云 , 刘馨烛 , 夏瑜彬 , 等 . 黄芪汤对慢性胆汁淤积继发肌少症大鼠骨骼肌细胞线粒体损伤的影响 [J]. 中华中医药杂志 , 2024 , 39 ( 1 ): 139 - 146 .
朱晓霞 , 贺宁 , 孟斌 , 等 . 中医食疗干预痰湿体质高血压病的临床疗效观察 [J]. 中华中医药杂志 , 2021 , 36 ( 8 ): 5106 - 5109 .
YUAN S , LARSSON SC . Epidemiology of sarcopenia: prevalence, risk factors, and consequences [J]. Metabolism , 2023 , 144 : 155533 . doi: 10.1016/j.metabol.2023. 155533 http://dx.doi.org/10.1016/j.metabol.2023.155533 .
俞佳瑛 , 徐楚芸 , 李宇 , 等 . 社区老年肌少-骨质疏松症高危人群的画像构建及护理建议 [J]. 中华护理杂志 , 2025 , 60 ( 14 ): 1757 - 1763 .
LIGTHART-MELIS GC , LUIKING YC , KAKOUTOU A , et al . Frailty, sarcopenia, and malnutrition frequently(co-)occur in hospitalized older adults: a systematic review and meta-analysis [J]. J Am Med Dir Assoc , 2020 , 21 ( 9 ): 1216 - 1228 .
GOPINATH B , RUSSELL J , FLOOD VM , et al . Adhe-rence to dietary guidelines positively affects quality of life and functional status of older adults [J]. J Acad Nutr Diet , 2014 , 114 ( 2 ): 220 - 229 .
LI X , HE J , SUN Q . Sleep duration and sarcopenia: an updated systematic review and meta-analysis [J]. J Am Med Dir Assoc , 2023 , 24 ( 8 ): 1193 - 1206 .
ZAKHAROVA A , KABASAWA K , ITO Y , et al . Association between sarcopenia and depressive symptoms in community-dwelling people aged 40 years and older [J]. Tohoku J Exp Med , 2022 , 257 ( 2 ): 117 - 125 .
TUTTLE CSL , THANG LAN , MAIER AB . Markers of inflammation and their association with muscle strength and mass: a systematic review and meta-analysis [J]. Ageing Res Rev , 2020 , 64 : 101185 . doi: 10.1016/j.exger. 2021.111544 http://dx.doi.org/10.1016/j.exger.2021.111544 .
PAN L , XIE W , FU X , et al . Inflammation and sarcopenia: a focus on circulating inflammatory cytokines [J]. Exp Gerontol , 2021 , 154 : 111544 . doi: 10.1016/j.exger. 2021.111544 http://dx.doi.org/10.1016/j.exger.2021.111544 .
RONG Y , BIAN A , HU H , et al . Study on relationship between elderly sarcopenia and inflammatory cytokine IL-6, anti-inflammatory cytokine IL-10 [J]. BMC Geriatr , 2018 , 18 ( 1 ): 308 .
LI X , WANG R , LU K , et al . Efficacy and safety of Shen-Qi Paste, a traditional Chinese medicine, in dialysis patients with sarcopenia: a randomized, double-blind, placebo-controlled trial [J]. Phytomedicine , 2025 , 147 : 157190 . doi: 10.1016/j.phymed.2025.157190 http://dx.doi.org/10.1016/j.phymed.2025.157190 .
KIM TY , PARK KT , CHOUNG SY . Codonopsis lanceolata and its active component Tangshenoside Ⅰ ameliorate skeletal muscle atrophy via regulating the PI3K/Akt and SIRT1/PGC-1alpha pathways [J]. Phytomedicine , 2022 , 100 : 154058 . doi: 10.1016/j.phymed.2022.154058 http://dx.doi.org/10.1016/j.phymed.2022.154058 .
郎爽 . 黄芪皂苷对D-半乳糖诱导的原发性骨骼肌减少的作用及其机制研究 [D]. 天津 : 天津中医药大学 , 2022 .
LEFEVRE C , BINDELS LB . Role of the gut micro-biome in skeletal muscle physiology and pathophysiology [J]. Current Osteoporosis Reports , 2022 , 20 ( 6 ): 422 - 432 .
贺云朋 , 吴俊果 , 王松波 , 等 . 油酰甘氨酸对C2C12成肌细胞增殖、分化和蛋白质沉积的影响 [J]. 农业生物技术学报 , 2016 , 24 ( 7 ): 1054 - 1063 .
0
Views
1
下载量
0
CSCD
Publicity Resources
Related Articles
Related Author
Related Institution
京公网安备11010102007558号